DBI

Across TCGA pan-cancer cohorts, DBI mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of DBI’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DBI mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DBI is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where DBI tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DBI mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.560	<.001	12	view →
HNSC	Female	All	−0.840	<.001	11	view →
LSCC	Female	All	−0.395	<.001	9	view →
LUAD	Male	III,IV	−0.473	<.001	8	view →
COAD	Female	III,IV	−0.653	<.001	7	view →
OV	All	All	−2.597	.007	2	view →
PDAC	Male	IV	−0.660	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

DBI–CCRCC

Open the CCRCC breakdown →